Literature DB >> 10835100

Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands.

F A de Wolf1, G M Brett.   

Abstract

Unstable or harmful agents, such as drugs, vitamins, flavors, pheromones, and catalysts, for use in pharmaceutics, personal care, functional foods, crop protection, laboratories, offices, and industrial processes, require stabilization against oxidation and degradation or shielding from sensitive environments. Therefore, binding them to carriers with high affinity and selectivity for targeting to the right environment and subsequent controlled release is beneficial, especially if this allows improved control of (stimulus-induced) release. Proteins often possess one or more of these properties, whereas modern biotechnology and bioinformatics provide an increasing number of tools to engineer and adapt these properties. Carrier systems are now developed that incorporate proteins as the central ligand-binding component, e.g., lectins for glucose-triggered release of glycosylated insulin and bispecific antibodies for brain targeting of drugs, but ligand-binding proteins can potentially be used in many other applications. Collectively, the proteins available in nature bind an impressive variety of ligands and non-natural analogs. In this light, various ligand-binding protein classes are surveyed, including biotin-, lipid-, immunosuppressant-, insect pheromone-, phosphate-, and sulfate-binding proteins, as well as bacterial periplasmic proteins, lectins, serum albumins, immunoglobulins, and inactivated enzymes. Disadvantages, such as enzymatic degradation or immunogenicity, associated with the pharmaceutical use of certain proteins can be avoided by incorporating these proteins in more complex carrier and targeting systems. In other applications, this may not be necessary. The enclosure of high-affinity (potentially stimulus-sensitive) binding proteins within an envelope that acts as a diffusion barrier for the ligand may provide excellent slow release. Many possibilities seem to be as yet unexplored.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835100

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  25 in total

1.  Modeling of human corticosteroid binding globulin. Use of structure-activity relations in soft steroid binding to refine the structure.

Authors:  Roy J Little; C G Rodríguez
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

Review 2.  Conformational dynamics and enzyme evolution.

Authors:  Dušan Petrović; Valeria A Risso; Shina Caroline Lynn Kamerlin; Jose M Sanchez-Ruiz
Journal:  J R Soc Interface       Date:  2018-07       Impact factor: 4.118

3.  Surfactant-free Colloidal Particles with Specific Binding Affinity.

Authors:  Casper van der Wel; Nelli Bossert; Quinten J Mank; Marcel G T Winter; Doris Heinrich; Daniela J Kraft
Journal:  Langmuir       Date:  2017-09-13       Impact factor: 3.882

4.  Effect of human serum albumin on the kinetics of 4-methylumbelliferyl-β-D-N-N'-N″ Triacetylchitotrioside hydrolysis catalyzed by hen egg white lysozyme.

Authors:  Cristian Calderon; Elsa Abuin; Eduardo Lissi; Rodrigo Montecinos
Journal:  Protein J       Date:  2011-08       Impact factor: 2.371

5.  Participatory role of zinc in structural and functional characterization of bioremediase: a unique thermostable microbial silica leaching protein.

Authors:  Trinath Chowdhury; Manas Sarkar; Biswadeep Chaudhuri; Brajadulal Chattopadhyay; Umesh Chandra Halder
Journal:  J Biol Inorg Chem       Date:  2015-05-06       Impact factor: 3.358

6.  Computational design of ligand-binding proteins with high affinity and selectivity.

Authors:  Christine E Tinberg; Sagar D Khare; Jiayi Dou; Lindsey Doyle; Jorgen W Nelson; Alberto Schena; Wojciech Jankowski; Charalampos G Kalodimos; Kai Johnsson; Barry L Stoddard; David Baker
Journal:  Nature       Date:  2013-09-04       Impact factor: 49.962

7.  Apolipoprotein A-IV reduces hepatic gluconeogenesis through nuclear receptor NR1D1.

Authors:  Xiaoming Li; Min Xu; Fei Wang; Alison B Kohan; Michael K Haas; Qing Yang; Danwen Lou; Silvana Obici; W Sean Davidson; Patrick Tso
Journal:  J Biol Chem       Date:  2013-12-05       Impact factor: 5.157

Review 8.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

9.  Mycobacterium tuberculosis is resistant to streptolydigin.

Authors:  Alexander Speer; Jennifer L Rowland; Michael Niederweis
Journal:  Tuberculosis (Edinb)       Date:  2013-04-13       Impact factor: 3.131

10.  A multicopper oxidase is required for copper resistance in Mycobacterium tuberculosis.

Authors:  Jennifer L Rowland; Michael Niederweis
Journal:  J Bacteriol       Date:  2013-06-14       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.